WO1997038740A1 - Compressed absorbent aggregate - Google Patents

Compressed absorbent aggregate Download PDF

Info

Publication number
WO1997038740A1
WO1997038740A1 PCT/US1997/004171 US9704171W WO9738740A1 WO 1997038740 A1 WO1997038740 A1 WO 1997038740A1 US 9704171 W US9704171 W US 9704171W WO 9738740 A1 WO9738740 A1 WO 9738740A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
compressed absorbent
weight
superabsorbent
absorbent aggregate
preceding
Prior art date
Application number
PCT/US1997/004171
Other languages
French (fr)
Inventor
Geoffrey G. Booth
Dwan F. H. Chowdhury
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L28/00Materials for colostomy devices
    • A61L28/0007Materials for colostomy devices containing macromolecular materials
    • A61L28/0026Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L28/00Materials for colostomy devices
    • A61L28/0034Use of materials characterised by their function or physical properties
    • A61L28/0049Hydrogels or hydrocolloids

Abstract

The present invention provides new compressed absorbent aggregates suitable for use in urostomy bags and the like. According to a presently preferred embodiment of the present invention there is provided a compressed absorbent aggregate comprising: 60 to 80 % by weight superabsorbent; 20 to 40 % by weight microcrystalline cellulose; and optionally 0.1 to 10 % by weight hydrophilic lubricant. The compressed absorbent aggregates may be in the form of tablets. This facilitates insertion into an ostomy bag, for example, via an integral addition port. The tablets are fast-disintegrating in the presence of aqueous media, generally taking from 1 to 10 minutes to disintegrate completely in the presence of sufficient water. The presence of the superabsorbent polymer promotes steady progressive thickening of the liquid into a gelled but flowable consistency without forming a stiff intractable gel. The thickened contents may be expelled from the bag via an integral valve, thus allowing for re-use of the bag.

Description

COMPRESSED ABSORBENT AGGREGATE

FIELD

This invention relates to compressed absorbent aggregates which are suitable for thickening human excretion products, particularly urine.

BACKGROUND Stoma patients who have been provided with intestinal passage by surgery empty the contents of the intestine into containers. These containers are usually plastic bags which are attached directly to the artificial intestinal passage and sealed off as tightly as possible. The same applies to patients who, owing to urinary fistula or for other reasons, have been given an artificial urinary passage. These patients have to cope with the problem that the excretion emptied into the collecting bag is frequently liquid. Moreover, it frequently develops an unpleasant smell owing to the increasing formation of gas. As a result, both the patient himself and those in the surrounding area may be considerably disturbed and inconvenienced. The liquid character of the excretion products, as in the case of urine and intestinal contents, may be ofa very thin consistency. Such a person may have to empty or change his or her urostomy pouch several times per day and between changes the pouch will often contain a quantity of liquid which sloshes about when the person moves. This is embarrassing and raises doubts in the wearer's mind as to the security of attachment of the pouch to the body, even though the attachment may be quite secure.

For this increasing proportion of stoma patients, it is extremely desirable for the excretion products (contents of the intestine or urine) to be thickened by simple measures to a consistency which corresponds approximately to the consistency of wallpaper paste. Such thickening will prevent undesirable slopping of the excretion products but allow the contents of the collecting bag to be readily emptied thus allowing for re-use of the bag. Various proposals have been made to incorporate superabsorbent materials, such as sodium polyacrylate, into urostomy bags and similar containers. Examples of such materials are disclosed in US-A-4179367, GB-A-2268882, GB-A- 1595687 and EP-A-0138427. However, none of the materials has found widespread acceptance by stoma patients.

SUMMARY

The present invention provides new compressed absorbent aggregates suitable for use in urostomy bags and the like. According to a presently preferred embodiment of the present invention there is provided a compressed absorbent aggregate comprising:

60 to 80% by weight superabsorbent

20 to 40% by weight microcrystalline cellulose; and optionally

0.1 to 10% by weight hydrophilic lubricant. The compressed absorbent aggregates may be in the form of tablets. This facilitates insertion into an ostomy bag, for example, via an integral addition port. The tablets are fast-disintegrating in the presence of aqueous media, generally taking from 1 to 10 minutes to disintegrate completely in the presence of sufficient water. The presence of the superabsorbent polymer promotes steady progressive thickening of the liquid into a gelled but flowable consistency without forming a stiff intractable gel. The thickened contents may be expelled from the bag via an integral valve, thus allowing for re-use of the bag.

DETAILED DESCRIPTION The main constituent of the aggregates of the invention is a superabsorbent.

Suitable superabsorbent materials are well known and generally comprise a water- insoluble but water swellable polymeric substance capable of absorbing water in an amount which preferably is at least 10 times the weight of the substance in dry form. Suitable superabsorbent materials are disclosed, for example in EP-A- 0138427. A preferred superabsorbent material for use in the invention is cross- linked sodium polyacrylate, such as the product commercially available from Allied Colloids under the trade name Salsorb 90. Salsorb 90 is available with a main particle size range of 100-850μm and as Salsorb 90 fines having an average particle size of about 150μm. Either material may be used, although the finer grade provides a smoother surface to tablets and slightly improved gelation performance in aqueous media due to its increased surface area. In general, a reduction in particle size below 150μm may improve some properties of the tablets while deleteriously affecting other properties, such as, hardness and gelation time.

Preferably the particle size is in the range 160 to 355 μm, more preferably 160 to

210μm. The superabsorbent is preferably present in an amount in the range 60 to 80% by weight of the aggregate, more preferably 65 to 75%, most preferably 67 to 72% by weight.

The aggregates of the invention also preferably comprise microcrystalline cellulose. Microcrystalline cellulose is an extremely compressible material. It is derived from a special grade of purified alpha wood cellulose by severe acid hydrolysis to remove the amorphous cellulose portions, yielding particles consisting of bundles of needle-like microcrystals. The majority of these microcrystals range in size from 1 to 10 microns.

Microcrystalline cellulose combines several properties ofa useful tabletting vehicle. These are filler, binder, disintegrant, lubricant and flow aid. While it is capable of producing very hard tablets, these tablets still are able to disintegrate rapidly in water due to swelling of the microcrystalline particles and destruction of the bonding forces holding them together. There are several particle sizes available, the choice largely dependent on the fluidity to be imparted to the formulation.

Microcrystalline cellulose is commercially available from FMC Coφoration under the trade name "Avicel". A preferred material for use in the invention is

Avicel PH101. The microcrystalline cellulose is generally used in an amount in the range 20 to 40% by weight of the aggregate, more preferably from 25 to 35%, and most preferably from 25 to 29% by weight of the aggregate.

When formed into a tablet the aggregates of the invention also preferably additionally comprises a hydrophilic lubricant. The lubricant helps prevent adherence of the granules to punch faces and dies used during tablet compression. In addition, it ensures smooth ejection of tablets from the die. Many known tabletting lubricants depend upon hydrophobic groups for their lubricant effect. However, it has been found that such lubricants have a deleterious effect on the disintegration and gelling properties of absorbent tablets and hydrophilic lubricants must be used in the materials of the invention. Suitable hydrophilic lubricants include polyethylene glycol (PEG), DL-leucine, glycine, sodium chloride, sodium benzoate, sodium stearyl fumarate, sodium lauryl sulphate. The preferred hydrophilic lubricant is polyethylene glycol grade 6000 (PEG 6000). The hydrophilic lubricant is generally used in an amount in the range from 0.1 to 10% by weight of the aggregate, more preferably 1 to 6% and most preferably 2 to 5% by weight.

The aggregates may include minor amounts of other excipients e.g. cosmetic additives such as colorants, deodorizers etc.

The compressed aggregates of the invention are conveniently in the form of tablets. The size and shape of the tablets may be varied. Generally, the tablets have a weight of from 1 to 5g. For example, 14mm round tablets provide a nominal weight of 1.5g per tablet and 23mm round tablets provide a nominal weight of 4g. The tablets preferably have a hardness (kp) of at least 5, more preferably at least 8, and an abrasion loss of no more than 2% by the test described hereinafter. Abrasion loss was measured on an Erweka tablet test machine Type TAD commercially available from Erweka Apparatebau GmbH. The machine was operated at a fixed speed of 25rpm and was equipped with an Abrasion Test Drum, 200mm in diameter and having internal paddle blades which carry the tablets to a certain height and then allows them to slide down, thereby causing them to rub together without hard impact.

The test procedure used samples of five tablets which were de-dusted and weighted (Wl). The weighed tablets were then placed in the test drum and allowed to rotate for five minutes. The tablets were then re-weighed (W2), having first removed any accumulated dust and results calculated in terms of percentage weight loss using the formula (W1-W2) x 100 ÷ Wl . This test is designed to determine the resistance of tablets to abrasion and shock likely to be experienced during manufacturing, packing, shipping and use.

The aggregates of the invention should preferably readily disintegrate in aqueous media. The time for complete disintegration in excess aqueous medium preferably is less than ten minutes, more preferably less than five minutes and most preferably less than one minute. In practice the aggregate will be subjected to progressive dilution with urine and should maintain an ongoing thickening action without forming a rigid gel (gel lock).

The aggregates of the invention may be prepared by blending the components of the formulation followed by compression. The components may be blended in a conventional mixing apparatus e.g. a Turbula T2C mixer. The abrasion loss and gelation performance of tablets have been found to be independent of blending times within the range of five to seventy minutes.

The blend of components may be compressed in conventional apparatus, such as tabletting machines. The compression dwell time has been found to significantly affect the properties of the compressed aggregate. In particular, abrasion loss is significantly reduced by employment of increased compression dwell time. For example, compression on a Manesty D tablet machine employing a turret equipped with 16 tooling stations operating at 17rpm, i.e. 272 tablets/minute, forms tablets having significantly reduced abrasion losses when compared to the same machine operating at 40rpm i.e. 640 tablets/minute. Many modern tablet machines are capable of operating at output levels of at least 80K to 100K tablets/hour, i.e. in excess of 1300 tablets/minute. The compression dwell time at such speeds is less likely to produce satisfactory tablets for use in the invention. The invention will now be illustrated by the following Examples. Unless otherwise stated all parts and percentages are by weight. Examples 1 to 3 The following formulations (%w/w) were prepared:

Figure imgf000008_0001

The formulations were blended and compressed into 1.5g tablets using a Manesty D tablet machine operating at an output level of approximately 270 tablets/minute. The machine comprised a turret equipped with 16 tooling stations and operated at 17rpm.

The tablets were examined and the disintegration/gelation performance examined by the addition of 100ml synthetic urine to three tablets at room temperature.

Example 1 produced a tablet having a pitted surface which crumbled on storage. Very fast disintegration (less than one minute) in synthetic urine achieved a gel of the required consistency.

Example 3 produced a good, stable tablet which disintegrated totally in less than ten minutes to achieve the required gel consistency.

Example 2 produced a good stable, tablet which achieved the required gel consistency following a somewhat longer disintegration time than that observed in Example 3.

Examples 4 to 9

Formulations were blended from a bulk mixture of 70 parts by weight

Salsorb 90 fines and 30 parts by weight Avicel PHI 01 and water soluble lubricants.

The individual lubricants were added in levels of 2, 4, 6, 8 and 10% by weight and compressed into tablets as in the previous Examples. The physical and gelation properties of the tablets were assessed. The lubricants used and results are reported in the following Table:

Figure imgf000009_0001

Examples 10 to 21 A series of tests were conducted to ascertain the effect of compression time, compression pressure and particle size of Salsorb on the properties of the tablets. The following formulations were used:

Figure imgf000009_0002

The components of each formulation were blended together for 7 minutes.

The formulations were compressed into tablets on the machine used in the previous Examples operated at different speeds. The hardness and abrasion loss of the tablets were measured and the gelation time determined following the addition of one tablet to 200ml of tap water and timing the period for disintegration. The results are reported in the following Table:

Figure imgf000010_0001

A further series of tests was conducted in which the formulations were formed into tablets using the machine of the previous Examples, operating at 17φm but varying the setting for compression pressure (IP 2P<3P<4P<5P<6P). The properties of the tablets were measured an results are reported in the following Table:

Figure imgf000010_0002

The results indicate reduction in machine speed, provides increased compression dwell time and generally results in reduced tablet abrasion loss. There is an optimum compression pressure giving the lowest abrasion loss and highest tablet hardness.

Additional tests were conducted using the same basic formulation as Examples 10 to 21 with the exception the Salsorb was sieved to produce fractions having a particle size of <150μm, <125μm and <90μm. Tablets were produced from the formulations in the tabletting machine operating at a speed of 17φm. It was found the reduction in particle size of Salsorb resulted in the following properties: improved smoothness of surface of the tablet; reduced abrasion loss; large increase in gelation time, and reduced hardness. Of the three size fractions tested, the coarsest size fraction gives the preferred balance of properties.

The performance of absorbent tablets was examined in synthetic urine formulation comprising an aqueous solution of urea and sodium chloride and minor amounts of other salts.

Tablets of Example 18 complying with formulations Al and A2 were tested as follows:

First, a tablet was dropped into a glass dish containing 100ml of synthetic urine. Gelation occurred for tablets of Al and A2 formulations within 90 seconds in the synthetic urine formulation.

Then, to determine minimum volume of synthetic urine required to cause gelation of one tablet glass dishes were prepared containing 50ml, 60ml, 70ml, 80ml, 90ml and 100ml of synthetic urine and one tablet introduced into each dish. For each tablet it was found that 60ml caused complete gelation with no free urine present. At >70ml the gel was less viscous with free urine present.

The normal rate of urine production in man is ~2ml/minute (120ml/hour) and thus there is a steady trickle of urine into the external urostomy pouch ofa patient. In order to mimic urine production/flow into a urostomy pouch two drip tests were conducted: First, a tablet was placed in a glass dish and synthetic urine dripped directly onto the tablet from a burette at a rate of one drop/second, equivalent to ~120ml/hour.

A second test was additionally performed. This test is identical to the previous test with the exception the synthetic urine was dripped into the glass dish to one side of the tablet. This was deemed to be a more realistic test since it is unlikely that urine will drip directly onto a tablet in a urostomy pouch.

In each test 60ml of synthetic urine was dripped into the glass dish containing one tablet.

Tablets of formulations Al and A2 gradually swelled as they absorbed the synthetic urine. After 60ml synthetic urine had been added a small part of the core of the tablets remained but this gradually disintegrated and gelled on standing. Thus, it can be expected that the tablets will perform effectively in a urostomy pouch.

Claims

CLAIMS:
1. A compressed absorbent aggregate, comprising:
60 to 80% by weight superabsorbent; 20 to 40% by weight microcrystalline cellulose; and
0.1 to 10% by weight hydrophilic lubricant.
2. A compressed absorbent aggregate according to Claim 1, comprising:
65 to 75% by weight superabsorbent; 25 to 35% by weight microcrystalline cellulose; and
1 to 6% by weight hydrophilic lubricant.
3. A compressed absorbent aggregate according to Claim 2, comprising:
67 to 72% by weight superabsorbent; 25 to 29% by weight microcrystalline cellulose; and
2 to 5% by weight hydrophilic lubricant.
4. A compressed absorbent aggregate according to any preceding Claim, wherein the superabsorbent is cross-linked sodium polyacrylate.
5. A compressed absorbent aggregate according to any preceding Claim, wherein the superabsorbent has a particle size in the range 160 to 355μm.
6. A compressed absorbent aggregate according to any preceding Claim, wherein the superabsorbent has a particle size in the range 160 to 210μm.
7. A compressed absorbent aggregate according to any preceding Claim, wherein the hydrophilic lubricant is selected from polyethylene glycol (PEG), DL- leucine, glycine, sodium chloride, sodium benzoate, sodium stearyl fumarate, sodium lauryl sulphate. 1
-12-
8. A compressed absorbent aggregate according to any preceding Claim, wherein the hydrophilic lubricant is polyethylene glycol grade 6000.
9. A compressed absorbent aggregate according to Claim 1, wherein the superabsorbent comprises cross-linked sodium polyacrylate having a particle size in the range 160 to 355μm and the lubricant comprises polyethylene glycol.
10. A compressed absorbent aggregate according to any preceding Claim, wherein the aggregate is in the form ofa tablet having an abrasion loss of not more than 2%.
11. A compressed absorbent aggregate according to any preceding Claim, wherein the aggregate is in the form ofa tablet having a hardness of at least 5kp.
12. A compressed absorbent aggregate according to any preceding Claim, wherein the aggregate is in the form of a tablet having a hardness of at least 8kp.
13. A compressed absorbent aggregate according to any preceding Claim, having a total disintegration time in excess aqueous medium at room temperature of less than 10 minutes.
14. A compressed absorbent aggregate according to Claim 1, having a total disintegration time in excess aqueous medium at room temperature of less than 1 minute.
15. A method of thickening human excretion products, comprising the step of: contacting said products with an effective amount ofa compressed absorbent aggregate comprising:
60 to 80% by weight superabsorbent; 20 to 40% by weight microcrystalline cellulose; and
0.1 to 10% by weight hydrophilic lubricant.
16. A method according to Claim 15, in which the compressed absorbent aggregate is introduced into an ostomy bag.
PCT/US1997/004171 1996-04-18 1997-03-14 Compressed absorbent aggregate WO1997038740A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9608033.8 1996-04-18
GB9608033A GB9608033D0 (en) 1996-04-18 1996-04-18 Compressed absorbent aggregate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19970917531 EP0897304A1 (en) 1996-04-18 1997-03-14 Compressed absorbent aggregate

Publications (1)

Publication Number Publication Date
WO1997038740A1 true true WO1997038740A1 (en) 1997-10-23

Family

ID=10792274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004171 WO1997038740A1 (en) 1996-04-18 1997-03-14 Compressed absorbent aggregate

Country Status (3)

Country Link
EP (1) EP0897304A1 (en)
GB (1) GB9608033D0 (en)
WO (1) WO1997038740A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815272A1 (en) * 2000-10-18 2002-04-19 Braun Medical Compressed superabsorbent product for absorbing body secretion, for use as colostomy or drainage bag, baby nappy or sanitary towel, comprises super-absorbent pulverized polymer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167433A1 (en) * 2000-06-19 2002-01-02 Mifa Ag Frenkendorf Product based on polysaccharides coprocessed with an insoluble disintegrant, process for its preparation and the use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179367A (en) * 1977-02-14 1979-12-18 Chemische Fabrik Thickening urinary and intestinal tract excrement
US4273761A (en) * 1977-04-12 1981-06-16 Nippon Kayaku Kabushiki Kaisha Method of enhancing absorption of antitumor agent into gastrointestinal tumor site and orally administrable antitumor compositions therefor
EP0138427A2 (en) * 1983-09-23 1985-04-24 Personal Products Company Compressed absorbent aggregate
GB2301350A (en) * 1995-06-22 1996-12-04 Squibb Bristol Myers Co Method and formulation for absorbing and treating waste

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179367A (en) * 1977-02-14 1979-12-18 Chemische Fabrik Thickening urinary and intestinal tract excrement
US4273761A (en) * 1977-04-12 1981-06-16 Nippon Kayaku Kabushiki Kaisha Method of enhancing absorption of antitumor agent into gastrointestinal tumor site and orally administrable antitumor compositions therefor
EP0138427A2 (en) * 1983-09-23 1985-04-24 Personal Products Company Compressed absorbent aggregate
GB2301350A (en) * 1995-06-22 1996-12-04 Squibb Bristol Myers Co Method and formulation for absorbing and treating waste

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815272A1 (en) * 2000-10-18 2002-04-19 Braun Medical Compressed superabsorbent product for absorbing body secretion, for use as colostomy or drainage bag, baby nappy or sanitary towel, comprises super-absorbent pulverized polymer
EP1199102A1 (en) * 2000-10-18 2002-04-24 B. Braun Medical Superabsorbent tablet and uses thereof

Also Published As

Publication number Publication date Type
GB9608033D0 (en) 1996-06-19 grant
GB2312213A (en) 1997-10-22 application
EP0897304A1 (en) 1999-02-24 application

Similar Documents

Publication Publication Date Title
US3499960A (en) Palatable coated particles of an anion exchange resin
US6569081B1 (en) Ostomy plug
US3903880A (en) Intrauterine device for managing the reproductive process
US4172120A (en) Cholestyramine compositions and method for treating biliary gastritis
US4069306A (en) X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US5888493A (en) Ophthalmic aqueous gel formulation and related methods
US4144317A (en) Device consisting of copolymer having acetoxy groups for delivering drugs
US5492937A (en) Gel-forming liquid carrier composition
US6039980A (en) Sustained release excipient
US6444199B1 (en) Solid borate-diol interaction products for use in wounds
US4561858A (en) Ostomy bag with integral breathable gasket
US5013769A (en) Method of making a hydrogel-forming wound dressing or skin coating material
US4393041A (en) Fibrin binder/carrier for active biochemical agents
US5135757A (en) Compressible sustained release solid dosage forms
US5932200A (en) Polyether polyurethane polymers, gels, solutions and uses thereof
US4069307A (en) Drug-delivery device comprising certain polymeric materials for controlled release of drug
US5073377A (en) Method of preparing oral dosage forms with a granulating composition
US4052505A (en) Ocular therapeutic system manufactured from copolymer
US4393080A (en) Adhesive compositions
US6332879B1 (en) Ostomy appliance
US3849185A (en) Method of preparing surgical sutures
US5065752A (en) Hydrophilic foam compositions
US5403593A (en) Melt granulated compositions for preparing sustained release dosage forms
US6451883B1 (en) Pressure Sensitive Adhesive Composition
US4534768A (en) Sealant pad for external catheter and method of use thereof

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A1

Designated state(s): US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997917531

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997917531

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997917531

Country of ref document: EP